menu
    • menu
    [{"orgOrder":0,"company":"Pulmocide","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Series C Financing","leadProduct":"PC945","moa":"CYP51","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmocide","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.089999999999999997,"dosageForm":"Inhalation","sponsorNew":"Pulmocide \/ Jeito Capital","highestDevelopmentStatusID":"8","companyTruncated":"Pulmocide \/ Jeito Capital"},{"orgOrder":0,"company":"Pulmocide","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Opelconazole","moa":"CYP51","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmocide","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Pulmocide \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmocide \/ Not Applicable"},{"orgOrder":0,"company":"Pulmocide","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Opelconazole","moa":"CYP51","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmocide","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension For Inhalation","sponsorNew":"Pulmocide \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Pulmocide \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Pulmocide","sponsor":"Pictet Alternative Advisors","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Series C Financing","leadProduct":"Opelconazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmocide","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.14999999999999999,"dosageForm":"Suspension","sponsorNew":"Pulmocide \/ Pictet Alternative Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Pulmocide \/ Pictet Alternative Advisors"},{"orgOrder":0,"company":"Pulmocide","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Opelconazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmocide","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Nebulizer","sponsorNew":"Pulmocide \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmocide \/ Not Applicable"},{"orgOrder":0,"company":"Pulmocide","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Opelconazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pulmocide","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Nebulizer","sponsorNew":"Pulmocide \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pulmocide \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Pulmocide

    Menu

    Pulmocide

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pulmocide

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Pulmocide

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Opelconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pulmocide Reports Successful Results from OPERA-S Phase 2 Safety Study with Opelconazole

                            Details : PC945 (opelconazole), is a potent novel azole therapy specifically designed for inhaled use to maximize the amount of drug in the lung while providing minimal systemic exposure.

                            Brand Name : PC945

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 15, 2024

                            Lead Product(s) : Opelconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pulmocide

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Pulmocide

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Opelconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pulmocide Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled Opelcon...

                            Details : PC945 (opelconazole), is a potent novel azole therapy specifically designed for inhaled use to maximize the amount of drug in the lung while providing minimal systemic exposure.

                            Brand Name : PC945

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 16, 2023

                            Lead Product(s) : Opelconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pulmocide

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Pulmocide

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Opelconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Pictet Alternative Advisors

                            Deal Size : $147.5 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole

                            Details : Pulmocide’s opelconazole is a potent novel azole therapy specifically designed for inhaled use to maximize the amount of drug in the lung while providing minimal systemic exposure.

                            Brand Name : PC945

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 06, 2022

                            Lead Product(s) : Opelconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Pictet Alternative Advisors

                            Deal Size : $147.5 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pulmocide

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Pulmocide

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Opelconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Cystic Fibrosis Foundation

                            Deal Size : $3.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            CF Foundation Invests $3.5 Million in Pulmocide for Development of Novel Antifungal Treatment for Lung Transpl...

                            Details : The CF Foundation’s funding will support Phase 2 study of opelconazole. The objective of the study is to assess the safety and tolerability and patient’s ability to complete the course of treatment when used to prevent invasive pulmonary fungal infec...

                            Brand Name : PC945

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 06, 2021

                            Lead Product(s) : Opelconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Cystic Fibrosis Foundation

                            Deal Size : $3.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pulmocide

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Pulmocide

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Opelconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pulmocide’s Lead Drug Candidate Opelconazole Granted Orphan Drug, Fast Track and Qualified Infectious Diseas...

                            Details : Pulmocide’s lead product is opelconazole (PC945), a novel antifungal therapy specifically designed for inhaled use to maximize the amount of drug in the lung and spare systemic exposure.

                            Brand Name : PC945

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 15, 2021

                            Lead Product(s) : Opelconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Pulmocide

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Pulmocide

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Opelconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Jeito Capital

                            Deal Size : $92.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945

                            Details : Proceeds from the financing will primarily be used to advance the Company’s lead asset PC945 through a global Phase III registration program in patients with invasive pulmonary aspergillosis (IPA) who have failed prior therapy.

                            Brand Name : PC945

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 27, 2021

                            Lead Product(s) : Opelconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Jeito Capital

                            Deal Size : $92.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth